Hereditary Antithrombin Deficiency
Medical filesBloodcells
HD OVERVIEWTreatment OptionsGTC CLINICAL TRIALSRESOURCESPHYSICIAN REGISTRY
Grid Imagery
Blood Droplet

The probablility of an HD patient developing thrombosis by 60 years of age can be as high as 80%





HD is associated with a significant risk of venous thrombosis in high-risk situations






Welcome to ATIII.com, Your Resource for
Information on Hereditary Antithrombin Deficiency

We are pleased to bring you this HD Web Site.  Our mission is to inform patients and physicians about our current clinical trial, to provide a forum for sharing information, and to enhance the health and lives of families affected by this coagulation disorder.

Antithrombin is an important anticoagulant in human serum.  It regulates thrombin, a blood protein that plays a key role in controlling clot formation.  Patients with Hereditary Antithrombin Deficiency, or HD, can have either Type I or Type II deficiency.  Type I is a quantitative deficiency characterized by low levels of antithrombin.  Type II is a qualitative deficiency characterized by the presence of antithrombin variants which do not function properly.  A survey of the literature suggests that Type I HD patients are generally more prone to venous thromboembolism than Type II patients.

Individuals with Hereditary Antithrombin Deficiency are at risk for blood clots, organ damage or even death.  Sometimes the clots can form spontaneously, putting an individual at sudden and unexpected risk.  Other research suggests that HD may contribute to fetal loss.  HD patients are perhaps at greatest risk during events which are independently associated with a probability of thrombosis, such as surgery and delivery.

We invite you to browse through the site, learn about new developments in the field, hear from patients and physicians, and post your own questions and comments.

Learn More


Divider Image HAVE YOU BEEN DIAGNOSED?
Learn about GTC's current trial using recombinant human antithrombin.
Learn more.

WHAT IS RECOMBINANT ANTITHROMBIN?
Recombinant Human Antithrombin, rhAT, is a new investigational agent and a potential therapeutic option for patients with HD.
Learn more.

NEW:STAR:

The National Alliance for Thrombosis and Thrombophilia (NATT)
Antithrombin Deficiency Brochure
Click Here to download


Read Taylor's Story
An HD patient discusses learning about, and living
with hereditary antithrombin deficiency.
Read it now
©2007 GTC-Biotherapeutics, Inc. All rights reserved.    Privacy Policy | Contact Us     GTC Biotherapeutics
ÿ